16 results · 22ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

BROWNE RAPICIDE GLUTARALDEHYDE INDICATOR

FDA 510(k)
FDA Class 2 ·General Hospital

SchureMed

FDA UDI
SCHUERCH CORPORATION·00810014607276·SKYTRON 3501B 4" SOFTCARE

RHIGENE MESACUP2 TEST- SCL-70

FDA 510(k)
FDA Class 2 ·Immunology

PACIFIC HEMOSTASIS INR CONTROL PLASMAS, MODEL CATALOG 100560

FDA 510(k)
FDA Class 2 ·Hematology

ECO HME

FDA UDI
GVS Technology (Suzhou) Co., Ltd.·15060120952650·

AMISTEM H FEMORAL STEM

FDA Adverse Event
Injury ·MEDACTA INTERNATIONAL SA·Product code LZO·April 8, 2013

PROFEMUR(R) MODULAR FEMORAL NECK

FDA Adverse Event
Injury ·WRIGHT MEDICAL TECHNOLOGY, INC.·Product code LWJ·May 6, 2011

SYNERGY

FDA Adverse Event
Injury ·MEDTRONIC PUERTO RICO OPERATIONS CO. MED REL·Product code LGW·July 23, 2008

INFINION CX

FDA Adverse Event
Malfunction ·BOSTON SCIENTIFIC NEUROMODULATION·Product code LGW·April 26, 2023

ARCHITECT CYCLOSPORINE REAGENT KIT

FDA Adverse Event
Malfunction ·ABBOTT IRELAND DIAGNOSTICS DIVISION·Product code MKW·August 8, 2025

INTIMA-II Y 24GAX0.75IN PRN EC SLM NPVC

FDA Adverse Event
Malfunction ·BECTON DICKINSON·Product code FOZ·September 4, 2025

ARCHITECT CYCLOSPORINE REAGENT KIT

FDA Adverse Event
Malfunction ·ABBOTT IRELAND DIAGNOSTICS DIVISION·Product code MKW·September 4, 2025

ABBOTT TUBE EDTA PLH 13X75 2.0 PNK

FDA Adverse Event
Malfunction ·BECTON, DICKINSON & CO. (BROKEN BOW)·Product code JKA·August 3, 2022

ABBOTT TUBE EDTA PLH 13X75 2.0 PNK

FDA Adverse Event
Malfunction ·BECTON, DICKINSON & CO. (BROKEN BOW)·Product code JKA·September 17, 2019

ARCHITECT CYCLOSPORINE REAGENT KIT

FDA Adverse Event
Malfunction ·ABBOTT IRELAND DIAGNOSTICS DIVISION·Product code MKW·September 30, 2025

CADD-Solis VIP ambulatory Infusion Pumps, Model 2110. Indicated for the following uses: Intra-arterial, subcutaneous, intraperitoneal, in close proximity to nerves, into an intraoperative site, epidural space or subarachnoid space. Therapies that require a continuous rate of infusion, intermittent bolus, and/or with patient-controlled demand doses.

FDA Enforcement
Class I ·Ongoing·Smiths Medical ASD Inc.·August 14, 2024